Humacyte Inc (HUMA)vsInsmed Inc (INSM)
HUMA
Humacyte Inc
$0.82
+3.60%
HEALTHCARE · Cap: $151.10M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 38501% more annual revenue ($606.42M vs $1.57M). HUMA leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
HUMA
Avoid16
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -2.5% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HUMA
HUMA has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : HUMA
The primary concerns for HUMA are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
HUMA profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
HUMA carries more volatility with a beta of 1.93 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
HUMA generates stronger free cash flow (-24M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 16/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Humacyte Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Humacyte Inc (HUMA) is a leading biotechnology company focused on transforming vascular and regenerative medicine through its development of innovative human acellular vessels (HAVs). By addressing the urgent clinical needs for vascular reconstruction and the treatment of chronic diseases, Humacyte aims to deliver off-the-shelf solutions that enhance patient outcomes and reduce healthcare costs. Leveraging its advanced technology platform, the company is well-positioned to lead advancements in transplantation and tissue engineering, ultimately making a substantial impact on the future of medical therapies.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?